Using genomic scars to select immunotherapy beneficiaries in advanced non-small cell lung cancer
H. C. Donker, B. van Es, M. Tamminga, G. A. Lunter, L. C. L. T. van Kempen, E. Schuuring, T. J. N. Hiltermann, H. J. M. Groen
This study identifies mutational signatures linked to immunotherapy response in NSCLC and develops a model to predict durable benefit.
bioRxiv · Sep 23, 2022 · PreprintCancer Biology